Work

The use of beta-sitosterol for the treatment of prostate cancer and benign prostatic hyperplasia.

Year: 2023

Type: article

Abstract: , particularly through its pro-apoptotic effect on prostate epithelial cells. Multiple studies also show that beta-sitosterol significantly improves lower urinary tract symptoms (LUTS) associated with BPH, but to an extent that is generally less effective than that achieved by pharmaceutical grade alpha-adrenergic receptor antagonists or 5α-reductase inhibitors. This latter finding suggests that supplements containing beta-sitosterol might be most appropriate for younger men with minimal LUTS who don't wish to embark on a clinical drug regimen for BPH treatment.

Source: PubMed Central

Author: Jill A Macoska

Institution: University of Massachusetts Boston

Language: English

Topic: Urinary Bladder and Prostate Research

Subfield: Urology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of Diabetes and Digestive and Kidney Diseases

Award: Cellular and molecular mediators of fibrosis in the development of urinary tract dysfunction